Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy-Reference-Cited by-同舟云学术

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

Published:2023-05-16 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Dastoli Stefano¹,Passante Maria¹,Loconsole Francesco²,Mortato Edoardo²,Balato Anna³,Piccolo Vincenzo³,Guarneri Claudio⁴,Macca Laura⁵,Provenzano Eugenio⁶,Valenti Giancarlo⁷,D’Amico Domenico⁷,Micali Giuseppe⁸,Musumeci Maria Letizia⁸,Palazzo Giovanni⁹,Foti Caterina¹⁰,Romita Paolo¹⁰,Fabbrocini Gabriella¹¹,Megna Matteo¹¹,Sammarra Ilaria¹²,Bennardo Luigi¹,Patruno Cataldo¹

Affiliation:

1. Department of Health Sciences, Magna Graecia University, Catanzaro, Italy

2. Clinical Dermatology, AOU Policlinico Consorziale Bari, Bari, Italy

3. Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy

4. Unit of Dermatology, Department of Biomedical, Dental Sciences and Morphological Imaging (BIOMORF), University of Messina, Messina, Italy

5. Unit of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

6. AO ‘Annunziata’, Cosenza, Italy

7. AO ‘Pugliese Ciaccio’, Catanzaro, Italy

8. UOC Dermatology Clinic University of Catania, Catania, Italy

9. Ospedale Distrettuale di Tinchi Pisticci, Azienda Sanitaria di Matera, Matera, Italy

10. Unit of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy

11. Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

12. Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2200868

Reference41 articles.

1. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

2. Secukinumab: First Global Approval

3. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

4. Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE , a randomized, double‐blind, placebo‐controlled trial

5. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study;Journal of Clinical Medicine;2024-06-30

2. Therapeutic Effects of 30 nm Cyclosporin A-Loaded Nanoparticles Using PLGA-PEG-PLGA Triblock Copolymer for Transdermal Delivery in Mouse Models of Psoriasis;Applied Sciences;2024-04-29

3. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort;2024-03-25

4. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea;Therapeutic Advances in Chronic Disease;2024-01

5. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report;Clinical, Cosmetic and Investigational Dermatology;2023-07